Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA covers the month of May 2020, specifically dated May 19, 2020. The report details the submission of an updated base prospectus for the Company's €10 billion European Medium-Term Note Program to the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Fresenius Medical Care AG & Co. KGaA. The document references the audited consolidated financial statements of the guarantor, Fresenius Medical Care Holdings, Inc. (FMCH), for the years ended December 31, 2019, and 2018, but does not summarize the numerical data within this text.
Material Changes
No material changes to financial performance or operations are reported in this filing. The primary update is the regulatory filing of the updated base prospectus for the €10 billion note program.
Guidance, Outlook, and Risks
- Program Details: Notes issued under the €10 billion program are guaranteed by Fresenius Medical Care Holdings, Inc. (FMCH).
- Regulatory Compliance: The filing includes FMCH financial statements to comply with Form 6-K requirements and Luxembourg Stock Exchange regulations.
- US Restrictions: Notes under the program may not be offered or sold in the United States absent registration under the US Securities Act of 1933 or an applicable exemption. They will not be offered to "US persons" as defined in Regulation S.
Investor Verification Checklist
- Verify the specific financial metrics (revenue, debt, liquidity) in the audited consolidated financial statements of FMCH for 2018 and 2019, referenced as Exhibit 99.1.
- Confirm the status of the €10 billion European Medium-Term Note Program approval with the CSSF.
- Review the terms of the guarantee provided by Fresenius Medical Care Holdings, Inc.
- Check for any subsequent filings regarding the actual issuance of notes under the program.